Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus
Authors:
Open Access
Abstract
Summary: Objective: To evaluate acute and long‐term effects of intravenous brivaracetam (BRV) and BRV + diazepam (DZP) combination treatment in a rat model of self‐sustaining status epilepticus (SSSE).Methods: Rats were treated with BRV (10 mg/kg) 10 min after initiation of perforant path stimulation (PPS) as early treatment; or BRV (10–300 mg/kg), DZP (1 mg/kg), or BRV (0.3–10 mg/kg) + DZP (1 mg/kg) 10 min after the end of PPS (established SSSE). Seizure activity was recorded electrographically for 24 h posttreatment (acute effects), and for 1 week at 6–8 weeks or 12 months' posttreatment (long‐term effects). All treatments were compared with control rats using one‐way analysis of variance (ANOVA) and Bonferroni's test, or Kruskal‐–Wallis and Dunn's multiple comparison tests, when appropriate.Results: Treatment of established SSSE with BRV (10–300 mg/kg) resulted in dose‐dependent reduction in SSSE duration and cumulative seizure time, achieving statistical significance at doses ≥100 mg/kg. Lower doses of BRV (0.3–10 mg/kg) + low‐dose DZP (1 mg/kg) significantly reduced SSSE duration and number of seizures. All control rats developed spontaneous recurrent seizures (SRS) 6–8 weeks after SSSE, whereas seizure freedom was noted in 2/10, 5/10, and 6/10 rats treated with BRV 200 mg/kg, 300 mg/kg, and BRV 10 mg/kg + DZP, respectively. BRV (10–300 mg/kg) showed a dose‐dependent trend toward reduction of SRS frequency, cumulative seizure time, and spike frequency, achieving statistical significance at 300 mg/kg. Combination of BRV (10 mg/kg) + DZP significantly reduced SRS frequency, cumulative seizure time, and spike frequency. In the 12‐month follow‐up study, BRV (0.3–10 mg/kg) + low‐dose DZP markedly reduced SRS frequency, cumulative seizure time, and spike frequency, achieving statistical significance at some doses. Early treatment of SSSE with BRV 10 mg/kg significantly reduced long‐term SRS frequency.Significance: These findings support clinical evaluation of BRV for treatment of status epilepticus or acute repetitive seizures.Keywords
Funding Information
- U.S. Department of Veterans Affairs (I01BX000273‐07)
- National Institute of Neurological Disorders and Stroke (UO1 NS074926)
This publication has 30 references indexed in Scilit:
- Intramuscular versus Intravenous Therapy for Prehospital Status EpilepticusNew England Journal of Medicine, 2012
- Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant propertiesEuropean Journal of Pharmacology, 2011
- The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticusEpilepsy Research, 2011
- Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2ABritish Journal of Pharmacology, 2008
- Dose translation from animal to human studies revisitedThe FASEB Journal, 2007
- Trafficking of GABAAReceptors, Loss of Inhibition, and a Mechanism for Pharmacoresistance in Status EpilepticusThe Journal of Neuroscience, 2005
- Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticusEpilepsy Research, 2004
- A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status EpilepticusNew England Journal of Medicine, 2001
- A Comparison of Four Treatments for Generalized Convulsive Status EpilepticusNew England Journal of Medicine, 1998
- A prospective, population-based epidemiologic study of status epilepticus in Richmond, VirginiaNeurology, 1996